




ROLE OF BIOMARKERS, KIDNEY INJURY MOLECULE-1, INTERLEUKIN-18, 
 
CALBINDIN AND MONOCYTE CHEMOTACTIC PROTEIN-1, IN EVALUATING 
 






































Discipline Optics and Imaging 
 
School of Laboratory Medicine and Medical Sciences 
 
College of Health Sciences 
 










This study represents original work by the author and has not been submitted in any other 
form to another University. Where use was made of the work of others, it has been duly 
acknowledged in the text. 
 
The research described in this dissertation was carried out in the Optics & Imaging Centre, 
College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa under the 
















































I, Dr. Soumaya Eltounali declare that: 
 
(i) The research reported in this dissertation, except where otherwise indicated is my original 
work. 
(ii) This dissertation has not been submitted for any degree or examination at any other 
University. 
(iii) This dissertation does not contain other person’s data, pictures, graphs or other 
information, unless specifically acknowledged as being sourced from other persons. 
(iv) This dissertation does not contain other persons writing, unless specifically 
acknowledged as being sourced from other researchers. Where other sources have been 
quoted, then: Their words have been rewritten but the general information attributed by 
them has been referenced. 
Where their exact words have been used their writing had been placed inside quotation 
marks and referenced. 
(v) Where I have reproduced a publication of which I am an author, co-author, I have 
indicated in detail which part of the publication was written by myself alone and have 
fully referenced such publications. 
 
(vi) This dissertation does not contain text, graphics, or tables copied and pasted from the 
internet, unless specifically acknowledged and the source being detailed in the 
dissertation and the reference sections. 
 


























To My Parent 
 
Strong and gentle souls who taught me to trust in Allah. Believe in hard work and that so 

























































I wish to express my sincere thanks and gratitude to: 
 
• My Supervisor and Co-supervisor, for the support, inspiration and the opportunity to 
be part of the Placental Research team. The guidance and assistance received has 
helped me to improve myself. 
 
• Optics and Imaging Centre, where this study was conducted. 
 
• The Placental Research Group, including my colleagues for their assistance. 
 
• My family, for their support, and encouragement throughout my research work. 
 
• Dr. Catherine Connolly (Biostatistics unit, University of KwaZulu-Natal) for assisting 
with the statistical analysis. 
 
• Dr. Adekomi Damilare Adedayo and Dr. Philemon Shallie for the grammatical 
corrections and computer typesetting. 
 
















































LIST OF FIGURES 
 













CHAPTER 1  1 
INTRODUCTION AND 2 
LITERATURE REVIEW  
1.0 Pre-eclampsia 2 
1.1 Epidemiology of Pre-eclampsia 4 
1.2 Risk factors 4 
1.3 The Kidney in Pregnancy 6 
1.4 Pathogenesis of Pre-eclampsia 7 
1.5 The role of angiogenic/antiangiogenic factors 10 






1.7 Kidney Injury Molecule-1 12 
1.8 Interleukin-18 14 
1.9 Monocyte chemotactic peptide-1 15 
1.10 Calbindin 17 
1.11 Kidney Injury in HIV Infection 18 
1.12 Highly Active Anti-Retroviral Therapy 19 
1.13 Hypothesis 21 
1.14 Aim 21 
1.15 Objective 21 
CHAPTER 2  22 
MANUSCRIPT SUBMITTED 23 
Role of kidney biomarkers [Kidney injury molecule-1, Calbindin, Interleukin-18 and 24 
Monocyte chemoattractant protein-1] in HIV associated pre-eclampsia.  
Abstract  24 
Introduction  26 
Method  28 
Discussion  30 
Conflict of Interest 34 
Acknowledgement 34 
References  35 
Tables and Figures 40 
CHAPTER 3  52 





3.1 Synthesis 53 
3.2 Conclusion 58 
3.3 Recommendation 59 
CHAPTER 4  60 
REFERENCES 61 
APPENDICES  74 
APPENDIX A  75 




















































Figure 1. Diagram showing the two stages of PE. 
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Figure 3: Pathways of IL-18 in the TH1 response. 
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Objective: This study was designed to measure the level of kidney injury molecule-1, 
calbindin, interleukin-18, and monocyte chemoattaractant protein-1 in pre-eclampsia, since 
the kidney is an organ of target in PE. This study was aimed at measuring the levels of these 
markers of kidney injury in the urine of HIV infected and uninfected women with normal 
pregnancy and pre-eclampsia. 
 
 
Study Design: The following study groups was included in the study; women with normal 
pregnancy who were HIV negative (n=19), women with normal pregnancy who were HIV 
positive (n=19), HIV negative pre-eclamptics (n=19) and HIV negative pre-eclamptics (n=19). 
 
 
Results: The concentration of KIM-1 in PE pregnancy was significantly higher than the level in 
normal pregnancy (p <0.05). Urinary KIM-1 level in the HIV negative women with PE was 
significantly higher than the level in the HIV negative women with normal pregnancy (p < 0.05). 
The urinary calbindin level was significantly higher in the PE group when compared to the level 
in the control group (p <0.05). The urinary IL-18 levels in the PE group did not show a 
significant deference when compared to the control group (p >0.05). There was no significant 
difference in the urinary MCP-1 in PE compared to the level in the controls (p >0.05). 
 
 
Conclusion: Our results show an increase in the urinary concentration of kidney injury 
molecule-1 and calbindin in PE, while the urinary Interleukin-18 and monocyte 





controls. We propose that studies with larger sample sizes and case control studies using these 
markers be conducted to establish their use as markers of diagnosing i kidney injury in PE. 
 
 




























































































































Pre-eclampsia (PE) is an obstetric complication of gestation which manifests after the 20th 
week of pregnancy, and one of the diagnostic feature aside the elevated blood pressure is the 
presence of protein in the urine (Watanabe et al., 2013). The cause of PE continues to be a 
question without answers as the cause is unknown. It affects women in both developed and 
developing countries (Hutcheon et al., 2011). 
 
The enormousness of the problems caused by PE is felt more by underdeveloped nations, 
where it is responsible for a greater percent of maternal and fetal deaths (Barra et al., 2012). 
Preventing and finding the cure of this disorder has been a topmost priority health agencies 
and the United Nations, the possibility of attaining this objective is still not feasible due to 
lack of adequate healthcare facilities in third world countries. PE is associated with grave 
complications such as preterm delivery, fetal and maternal death (Barra et al., 2012). 
 
 
During the course of normal gestation, the process of placental development and formation is 
highly regulated, this process involves the cytotrophoblast cells invading the maternal uterine 
wall thereby causing the placental spiral artery to be remodelled and converted into larger 
blood supplying channels (Eastabrook et al., 2011). Aberration in this process and altered 
spiral artery remodelling is associated with PE and this manifest as diminished blood flow to 
the placenta, followed by ischaemia of the placenta (Naljayan and Karumanchi, 2013). 
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There are other associated factors known to contribute to the pathogenesis of PE, these 
include an imbalance in the concentration of pro-inflammatory substances in maternal 
circulation, endothelial damage, placental hypoxia and resulting endoplasmic reticulum stress 
(Tannetta and Sargent, 2013). .The corner stone of treatment is the delivery of the baby and 




Women affected with PE may come down with severe complications such as seizures leading 
to coma and may result in death (Souza et al., 2013). This complication of pregnancy (PE) 
affects almost all the organs and systems in the body, it causes unfavourable changes in the 
intrauterine environment and also causes activation of adverse cellular signalling which may 
be harmful to foetal development (Goulopoulou and Davidge, 2015). 
 
 
Pre-eclampsia may be superimposed on existing hypertension. This occurs in women who 
were hypertensive before getting pregnant but didn’t manifest proteinuria (Magee et al., 
2014). Superimposed PE may be initiated by an underlying condition of the kidney (Magee 
et al., 2014). Severe cases of PE may result in seizures, this manifest before the onset of 
labour, during labour or after labour (Watanabe et al., 2013). Associated with the 
development of eclamptic seizures in PE includes; vasospasm of the cerebrum, as well as 












1.1 Epidemiology of pre-eclampsia 
 
Hypertensive disorders of pregnancy (HDP) causes about 62,000 to 77,000 maternal deaths 
globally each year, this translates to approximately 18% of all the cases of maternal deaths 
(Abalos et al., 2013). Underdeveloped economies are the worst hit as the probability of 
pregnant woman dying from HDP is 1 out of 39 compared to the ratio of 1:3800 in the 
advanced countries (Abalos et al., 2013). It has also been stated that PE accounts forE in 
pregnancy globally (Jeyabalan, 2013). 
 
 
In South Africa, a total of 4452 maternal deaths was reported from 2011 – 2013 ,the 
percentage of maternal deaths due to hypertension associated with pregnancy being 14.8% of 
this total figure. The value in KwaZulu – Natal Province stood at 8.3 % of the national figure 
(Saving Mothers Report, 2011-2013). 
 
 
1.2 Risk factors associated with the development of pre-eclampsia 
 
Pre-eclampsia development is known to be facilitated by some risk factors. Risk factors 
involved in PE development include history of vascular diseases and high blood pressure, 
maternal over weight, current or previous history of renal complications, presence of 
metabolic disorders such as diabetes (Villar et al., 2006). It has also been stead that maternal 
age at the time of conception, nulliparity, an extended period between  pregnancies, and 
multiple gestations are additional factors which predispose women to developing PE (Villar 






Pre-eclampsia may also result from an underlying genetic condition which may predispose 
women to developing this complication of pregnancy (Powe et al., 2011; Lin et al., 2015). 
Also implicated in the development of PE is change in paternity and change in partners by 
woman from a previous pregnancies, the use of condoms and other barrier contraception 
resulting in a decreased maternal exposure to paternal antigens, this thus poses a danger to 
women and predisposes the woman to developing pre-eclampsia (Powe et al., 2011). 
 
 
Pre-eclampsia can be classified either based on the onset or on the severity of this 
hypertensive complication of pregnancy. Based on the severity of PE, it is classified as mild 
PE or severe PE (Watanabe et al., 2013). 
 
 
• Mild form of PE is defined by a blood pressure of ≥ 140/90 mmHg and < 160 mmHg, 
a urine protein concentration of ≥ 300 mg but not above a value of 2.0 g in 24 hour 
urine (or 2 pluses (+) on a dipstick) (Watanabe et al., 2013). 
 
• Severe form PE is defined by a blood pressure of ≥ 160/110 mmHg, with a urine 
protein concentration > 2.0g in a 24 hour urine (or 3 pluses (+) on a dipstick) 
(Watanabe et al., 2013). 
 
 
The second classification of PE is based on onset of the disorder. With this, PE is classified 
as early onset PE which occurs before the 34th week of gestation (≤ 33 weeks 6 days). The 
late form of PE occurs 34 or after 34 weeks post conception (Lisonkova and Joseph, 2013). 
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1.3 The kidney in pregnancy 
 
During the course of pregnancy, glomerular filtration rate (GFR) is increased by almost 40% 
to 60% in the first trimester. In pregnancy with complications like PE, there is a decrease in 
both GFR and renal plasma flow by 30% to 40% as compared to that in a normal pregnancy 
(Moran et al., 2003; Karumanchi et al., 2005). In PE, blood urea nitrogen (BUN) and 
creatinine levels may be within the normal physiological range for non-pregnant women 
notwithstanding the decrease in GFR (Karumanchi et al., 2005). 
 
 
In PE impaired kidney function is associated with podocytopathy (Garovic et al., 2007). 
Podocyte injury results in loss of podocyte integrity and function, this activates a 
dedifferentiation process characterised by insufficient adherence to the glomerular basement 
membrane (GBM). This inadequate adherence of the popdocytes to the GBM results in its 
loss in the urine (podocyturia) (Hara et al., 2005). Disorientation of the GBM lends support 
to the progress of synechiae and glomerulosclerosis, which presents clinically as protein in 
the urine (proteinuria) (Facca et al., 2012). 
 
 
Endotheliosis is a glomerular capillary lesion associated with PE. This lesion can be seen using 
light microscopy, the cells of the glomeruli will appear are enlarged than normal, another 
distinguishing feature seen with light microscopy is a bloodless glomerular capillary lumen due 
the characteristic hypertrophy of endothelial and mesangial cells (Karumanchi et al., 2005). 
Though endotheliosis is also seen in other conditions, it is more prominent in PE. Podocytes 
mostly appear swollen ‘’with periodic Acid-Schiff (PAS)-positive hyaline droplets’’. The 




fenestrae can be established with electron microscopy (Churg and Grishman, 1976). Studies 
have shown that mild glomerular endotheliosis is seen in about 50% of patients with 
pregnancy-induced hypertension without proteinuria (Nochy et al., 1980), this therefore 
suggest that PIH in some cases may be a reflection of a milder form of the same condition 
(Karumanchi et al., 2005). It has also been stated that endothelial swelling seen in PE usually 
resolve within 8 weeks post-delivery, this also coincides with the termination high blood 
pressure and proteinuria (Karumanchi et al., 2005). 
 
 
The cause of PE remains unknown but studies have shown that altered spiral artery 
remodelling and subsequent reduction in uteroplacental blood flow which results in  impaired 
trophoblast invasion of the placental spiral artery is a factor responsible for the development 
of PE (Barra et al., 2012). The development of this obstetric complication of pregnancy 
occurs in two stages as seen in Figure 1. 
 
 
1.4 Pathogenesis of pre-eclampsia 
 
The first stage of PE is the pre-clinical stage and the second stage of the disorder is the 
clinical stage (Tannetta and Sargent, 2013). The preclinical stage of PE development is 
associated with poor placenta development. Poor placentation results from shallow invasion 
of the uterine wall by cytotrophoblast cells, alteration in the process of placenta spiral artery 








































Placenta dysfunction starts in the period of gestation (stage 1). Second stage of PE is 
associated with the release of trophoblast derived factors into maternal circulation, these 
particles stimulate inflammatory response and cause dysfunction of maternal vascular 
endothelium (Borzychowski et al., 2006). 
 
The key event in normal placentation is the invasion of the maternal spiral arteries to the 
decidua and the inner third of the myometrium by the foetal trophoblast cells. Early in 
normal placental development, cytotrophoblast cells of foetal origin breaks through the 
syncytium and migrates into the endometrium (Figure 2) (Karumanchi et al., 2005). During 
this process the spiral artery is invaded and converted into larger conduits for the supply of 
blood to the placenta.  
Research shows that placental ischaemia in PE occurs as a result of defective placental spiral 
artery remodelling. In PE, invasion of the spiral artery is shallow, and the spiral arteries remains 
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as small resistance channels, resulting in reduced utero-placental perfusion and subsequently 




The hypoxic placenta is thought to synthesize and release elevated amounts of sFlt-1 and 
sEng (Young et al., 2010). Furthermore, an ischaemic placenta contributes to endothelial cell 
dysfunction in the maternal vasculature by inducing an alteration in the balance of circulating 












































The second stage of PE (Figure 1) is characterised by damaged syncytial architecture, with the 
release of trophoblast derived factors/ debris into the circulation. This stage of the disorder is also 
associated with increased peripheral vasoconstriction, and loss of arterial compliance (Tannetta 
and Sargent, 2013). In the clinical stage of PE, the placenta is stressed and it releases molecules 
such as the soluble vascular endothelial growth factor receptor-1 (VEGFR1 or the sFlt-1) and 
also soluble endoglin (sENG), which are both known to cause a disorganization of fenestrated 
endothelium. The molecule vascular endothelial growth factor (VEGF) is needed for maintaining 
the integrity of fenestrated endothelium. In PE, there is an imbalance in the circulating levels of 
angiogenic and ant-angiogenic molecules. There is up regulation of and over production of anti-
angiogenic (sEng, sFlt-1) molecules in PE compared to the level in normal pregnancy important 
for its integrity (Redman, 2011). While the level of angiogenic (VEGF) molecules is diminished. 
Alteration in the orientation of the fenestrated endothelium manifests as the leakage of protein 
into the urine (Craici et al., 2013). 
 
 
1.5 The role of angiogenic/antiangiogenic factors in pre-eclampsia 
 
Ischemia of the placental cells results in them secreting soluble factors in to circulation, these 
factors which are anti-angiogenic may cause maternal endothelial dysfunction (Maynard et al., 
2003). Disruption in the balances between angiogenic and antiangiogenic factors is critical to the 
pathogenesis of PE. Two antiangiogenic factors, soluble fms-like tyrosine kinase 1 (sFlt-1) and 
soluble endoglin (sEng) have been shown to play a great role in the pathogenesis of PE. 
 
 
The anti-angiogenic molecule sFlt-1 is a splice variant of the membrane bound VEGF receptor 
Flt1, it is mainly secreted and released into the circulation by syncytiotrophoblast cells (Young 
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et al., 2010). Elevated levels of sFlt-1 is associated with diminished placental growth factor 
(PLGF) and vascular endothelial growth factor (VEGF) signalling (Levine et al., 2004). 
Soluble fms-like tyrosine kinase-1 prevents VEGF and PLGF from carrying out their normal 
function by binding to them in circulation and inhibiting their interaction with receptors 
meant for their function (Maynard et al., 2003). 
 
 
Another peptide molecule indicted in the pathogenesis of PE is soluble endoglin (sEng), it is 
an antiangiogenic protein. This molecule is highly expressed on endothelial cell membranes, 
syncytiotrophoblast cells and invading cytotrophoblast cells (Powe et al., 2011). Soluble 




1.6 Kidney Biomarkers in pre-eclampsia 
 
In PE, renal injury with release of protein into the urine is a characteristic feature, but the 
extent of insult to different segments of the nephron is not well known. Kidney injury in PE 
can also be defined by total urinary protein excretion in a 24 hour period to the concentration 
of creatinine randomly collected urine samples (Burwick et al., 2014). Renal injury is 
characterised by changes occurring at both cellular levels and molecular levels which result 
in kidney insufficiency and also structural renal damage. The conventional biomarker used in 
the diagnosis of renal injury clinically is creatinine. The use of creatinine alone is not able to 
predict kidney nephrotoxicity, is limited (Peres et al., 2013), hence there is need for novel 
biomarkers to be used in the diagnosis of kidney injury. An ideal biomarker for the diagnosis 
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of kidney injury should be a marker that is easy to quantify and also able to establish insult to 
the kidney at an early stage of the condition (Cullen et al., 2012). 
 
 
Extensive research employing the use of several kidney injury biomarkers have been carried 
out and these biomarkers have proven to be of great value in cases of ischemic injury, in both 
experimental and clinical scenario (Endre et al., 2011). Studies have been designed on the 
different urinary markers associated with PE, this involves the use of urinary biomarker 
panels to measure different markers of kidney injury which are specific for the different 
segments of the renal nephron (Burwick et al., 2014). These markers include albumin, β2 
macroglobulin (B2M), C, epithelial growth factor (EGF), kidney injury molecule-1 (KIM-1), 
neutrophil gelatinase–associated lipocalin (NGAL), osteopontin (OPN), MCP-1, IL-18, 
calbindin and uromodulin (UMOD) (Burwick et al., 2014). These markers have shown to be 
of great value in the diagnosis of kidney injury. These study is designed to quantify the level 
of urinary KIM-1, IL-18, calbindin, and MCP-1 in pre-eclampsia. 
 
 
1.7 Kidney Injury Molecule-1 (KIM-1) 
 
The kidney injury molecule -1 (KIM-1) is a transmembrane glycoprotein molecule (type-one), it 
has an immunoglobulin domain and mucin. This molecule is not detectable in physiological 
kidney conditions as well as in the urine in normal conditions (Peres et al., 2013). This biomarker 
is expressed in the proximal tubular cells of the kidney post ischemic or toxic damage. The KIM 
-1 concentration is markedly elevated in human as well as in rodents 24-48 hours in the cells of 
the kidney proximal tubule after an ischemic injury (Peres et al., 2013). Studies has shown that a 




with proximal tubular injury, hence this molecule can be used as a marker for the diagnosis 




Studies have revealed that the urinary level of KIM-1 correlated with the clinical outcome of 
the disease. In normal kidneys, the gene expression of the profile of KIM-1 is diminished or 
completely down regulated, but in cases of kidney injury the messenger ribonucleic acid 
(mRNA) of KIM-1 is produced at a fast rate (Slocum et al., 2012). Information obtained 
from the structure and expression data of KIM-1 shows that this molecule novel epithelial 
cell adhesion molecule (CAM) which is up-regulated in proximal tubular cells which are 
redeveloping, these regenerating cells are known to fix the injured section of the kidney 
nephron in a post ischemic kidney (Ichimura et al., 2008). 
 
 
In conditions of ischemic or toxic acute kidney injury in humans, KIM-1 is expressed on 
cells of all three sections of the proximal tubules, but what makes this molecule unique and 
good marker of kidney injury is the fact that KIM-1 is not expressed on normal kidney cells 
(Slocum et al., 2012; Peres et al., 2013). Another peculiar feature is the increased 
‘‘expression and in insertion into the apical membrane of the proximal tubule, and its 
persistence in the epithelial cell until the cell’s full recovery’’ (Peres et al., 2013). 
 
 
In PE urinary KIM-1 level is markedly increased, this is supported by the fact that KIM-1 is up 
regulated by epithelial cells of the proximal tubule in reaction to ischemia of the renal cells 
(Burwick et al., 2014). Studies have also shown that expression of this molecule transforms 
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proximal tubule epithelial cells into cells that act like macrophages to eliminate cellular debris 
from injured tissues (Ichimura et al., 2008). It has also been shown in mouse models that up 
regulation of KIM-1 post ischemic injury mediates activation of the complement system in the 
proximal tubule (Peng et al., 2012). Burwick et al., (2014) have established that there exist a 
correlation between increased urinary KIM-1 level and activated complement components PE. 
 
 
1.8 Interleukin-18 (IL-18) 
 
Interleukin-18 (IL-18) is a pro-inflammatory molecule with interspersed expression in cells of the 
distal convoluted tubule as well as in cells of the collecting tubule in normal physiological 
conditions (Peres et al., 2013). These renal cells expressing IL-18 possess three major 
components needed for release of the active form of this cytokine, these are ‘‘pro-IL-18: the 
P2X7 and caspase-1 intracellular cysteine protease” (Figure 3; Dinarello, 1989), they convert the 
pro-form of this cytokine into the active form. The active form of IL-18 then leaves the tubular 
cell to the lumen thus impacting on the urinary levels in acute kidney injury (Ichimura et al., 
2008). 
 
The urinary concentration of IL-18 is elevated in human studies and it has a high sensitivity and 
specificity to detect injury and damage to tubular cells, thus it can serve as a marker of kidney 
toxicity. This is a unique marker as its level is markedly increase before an increase in the level 
of serum creatinine becomes visible (Peres et al., 2013). The concentration of urinary IL-18 early 
in kidney injury conditions correlate with the severity of damage. The concentration of urinary 
IL-18 may be considered as a marker of diagnosing injury to the kidney, but the pro-
inflammatory nature of this cytokine and its  
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concentration in several inflammatory diseases may limit the use as this would affects its 



























Figure 3. Pathways of IL-18 in the TH1 response (Dinarello, 1989) 
 
 
IL-18 is a mediator of renal ischemic reperfusion injury that induces monocyte and 
neutrophil infiltration of the renal parenchyma, it is well know that PE is associated with 
ischaemia. Also, IL-18 increases in the urine during apoptosis (Adiyanti and Loho, 2012), PE 
is considered to be associated with increased apoptosis (Tannetta and Sargent, 2013). 
 
 
1.9 Monocyte chemotactic peptide-1 (MCP-1) 
 
The kidney marker, MCP-1 plays crucial role in part pathogenesis of renal injury. This has been 
shown by various studies in animal models as well as in humans. It is implicated in driving 
tubulo-interstitial injury (Viedt and Orth, 2002), and the expression of MCP-1 by cells of the 
glomerulus correlates with the extent of injury to kidney cells (Panzer et al., 2001). It has been 
shown that in humans with crescentic glomerulonephritis, this molecule (MCP-1) expressed 
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both the epithelial cells of the kidney tubules and the leukocytes infiltrating the interstitium 
of the tubules (Segerer et al., 2000). Experimental research has shown that the degree of 
proteinuria diminishes with the administration of MCP-1 antibodies in crescentic 
glomerulonephritis and ameliorates renal kidney (Wada et al., 1996). 
 
 
Elevated level of urinary MCP-1 is seen in patients with a disorder of the kidney, the urinary 
MCP-1 Concentration shows a strong correlation with the extent of albuminuria/ proteinuria 
and kidney injury (Stephan et al., 2002). Monocyte chemotactic peptide-1 mRNA was shown 
to be up regulated in ischemia-reperfusion injury, and MCP-1 has been described as a marker 
of ‘‘mononuclear inflammatory processes’’(Peres et al., 2013) which occurs post-ischemia in 
kidney injury. This molecule is a powerful chemokine which is secreted by renal cells and is 
a mediator of kidney toxicity (Peres et al., 2013). 
 
Studies in murine models have shown that the MCP-1 protein as well as the mRNA were 
elevated in intra-renal injuries in a high concentration. Urinary MCP-1 level may be of value 
in the diagnosis of kidney injury (Munshi et al., 2011). Monocyte chemoattractant peptide-1 
has been shown in-vitro to activate renal tubular epithelial cells, the mechanism behind this is 
not known (Viedt and Orth, 2002). This ability of MCP-1 to activate renal tubular epithelial 
cells is in line with the fact it plays a role in tubulo-interstitial inflammation, a mark of 














Calbindin also known as calbindin-D28K, is an intracellular calcium binding protein, 
localised in the distal tubular cells and also in the proximal part of the collecting duct. Injury 
to the distal segment of the kidney nephron may affect the expression of this molecule and 





















Figure 4: Ca 2+ -binding Calmodulin (3cln) Ca 2+ -free Calmodulin (1cfc) Triggering Calbindin D 9K (1b1g) 
 
Thermolysin (1tlx). (lithium.gsu.edu/faculty/Yang/Protein/lecture2_tertiary%20structure.ppt) 
 
 
Though the exact role of this molecule is yet to be established, calbindin is as a carrier 
molecule that participates in the transportation of transcellular Ca2+. It also acts as buffer 
keeping the level of Ca2+ normal and not allowing the level to be  toxic.Additionally, it 
modulates the release of insulin from cells of the pancreas, and acts as an inhibitor of cell 
death (Figure 4; Timurkaan and Tarakci, 2004). 
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It has been reported in rat models with unilateral urethral obstruction that the calbindin protein 
expression level was noticeably down regulated in the kidney distal nephron, these authors also 
found a mark decrease in calbindin mRNA expression in kidney that are hydronephrotic (Iidaet 
al., 2014). Morphological alteration in the kidney cellular arrangement explains the 
diminished calbindin expression in the distal nephron, emanating from increased stress, 
dilation of renal tubular lumen and the degeneration of renal epithelial cells (Iida et al., 
2014). Altered calbindin production can further be explained the generalised cellular 
disturbance of the distal nephron. The concentration of calbindin excreted is dependent on 
the time of disease onset, patient age and the serum calcium level. Low concentration of 
urinary calbindin is linked to a diminished expression of this molecule on the renal cells 
resulting from damaged renal distal nephron (Iida et al., 2014). 
 
 
1.11 Kidney injury in HIV infection 
 
Kidney injury in HIV infected people is occurring more frequently than in uninfected 
individuals (Campos et al., 2016). Renal injury in individuals infected with HIV is associated 
with the severe opportunistic infections just as it is with the drugs used in for anti-retroviral 
therapy (Kalim et al., 2008; Ibrahim et al., 2010). Common kidney biopsy features in HIV 
infected persons with acute kidney injury include glomerular disorder and presence of drug-
induced microtubular obstruction (Rao and Friedman, 1995). Studies have shown that in 
some settings nephrotoxicity is responsible for approximately 30% of cases of acute kidney 
disease in HIV infection (Randall et al., 2014).  
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Treatment regimen used in the treatment of HIV associated infections have been linked to the 
development of kidney conditions, an example of such ‘‘drugs are aminoglycosides, 
pentamidine, amphotericin and trimethoprim/sulfamethoxazole, and antivirals such as 
acyclovir and foscarnet’’(Campos et al., 2016). 
 
Though the chance of a single or particular antiretroviral drug causing renal toxicity is low, 
so many factors are implicated in making HIV infected individuals susceptible in developing 
kidney injury (Roe et al., 2008; Wikman et al., 2013). Infection with HIV and the use of anti-
retroviral drugs are linked to the development of chronic kidney disease. The prevalence of 
chronic kidney injury in HIV-infected persons in ‘‘North America and Europe ranges from 
4.7 to 9.7%’’ (Campos et al., 2016), this prevalence increases to about 33% if chronic kidney 
disease is defined by diminished glomerular filtration rate (GFR) or the manifestation of 
pathological proteinuria (Szczech et al., 2002). The chance of HIV infected patients 
developing chronic kidney conditions isincreased in conditions underlying HIV infection 
such as diabetes as well as high blood pressure (Mocroft et al., 2010). In Africans infected 




Kidney cell injury may occur from direct infection or from the response of immune cells to 
the antigenic stimulation of viral particles. The combination of anti-retroviral drugs, effects 
of therapeutic drugs used to treat associated infection with HIV, together pose a great risk in 
the development of kidney disorder in HIV patients (Campos et al., 2016). 
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1.12 Highly active antiretroviral therapy (HAART) 
 
The use of highly active antiretroviral therapy (HAART) has helped reduce mortality and 
morbidity resulting infection with the human immunodeficiency virus (Izzedine et al., 2009). 
A number of adverse kidney side effects are associated with the use of this drugs. Individuals 
infected with HIV may develop chronic metabolic conditions associated with the use of 
HAART like diabetes and dyslipidaemia. These metabolic disorders may lend support to 
vascular and renal dysfunction (Izzedine et al., 2009). 
 
 
Acute kidney injury seen in HIV infection mostly are a product of opportunistic infections 
than the toxic effect antiretroviral drugs. Studies have revealed that nephrotoxicity from 
antiretroviral therapy accounts for approximately 14% of late-onset cases of acute kidney 
injury (Roe et al., 2008). A major cause of kidney injury in HIV infection could be due to is 
acute interstitial nephritis which be due HIV infection itself, or presence of an opportunistic 
infection or direct drug cytotoxicity (Rho and Perazella, 2007; Izzedine et al., 2009). 
 
 
Normal kidney function is crucial to metabolism and excretion of antiretroviral drugs. This 
exposes the kidney to insult from some of these therapeutic agents (Kalyesubula and 
Perazella, 2011). The clinical presentation of HAART induced kidney injury includes 
alteration in electrolyte and acid-base balance, lactic acidosis, both acute and chronic kidney 
conditions. HAART induced kidney injury occurs through numerous mechanism, which may 
be direct tubular injury or may be in the form of allergic reactions, accumulation of dug 
precipitates within the kidney tubule lumen (Kalyesubula and Perazella, 2011). 
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Apart from nephrotoxicity associated with the use of antiretroviral drugs, the HIV particle 
can directly cause injury to the renal cells, this can be seen in cases of HIV-associated 
nephropathy (Campbell et al., 2009; Choi et al., 2009). Other conditions which result from 
HIV infection that affect kidney function include HIV immune-complex kidney disease and 











To identify and quantify the urine level of KIM-1, IL-18, calbindin and MCP-1 in HIV 





• To measure urinary levels of MCP-1, IL-18, KIM-1 and calbindin across all the study 
groups. 
• To compare levels of MCP-1, IL-18, KIM-1 and calbindin based on the type of 
pregnancy (pre-eclamptic and normotensive pregnant women). 
• To compare urine levels of MCP-1, IL-18, KIM-1 and calbindin based on the 
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Role of kidney biomarkers [Kidney injury molecule-1, Calbindin, 




































Role of kidney biomarkers [Kidney injury molecule-1, Calbindin, Interleukin-18 and 





Objective: Both HIV infection and pre-eclampsia (PE) are associated with considerable 
maternal mortality in South Africa. This study was designed to compare the urinary levels of 
kidney injury molecule-1 (KIM-1), calbindin, interleukin-18 (IL-18), and monocyte 
chemoattractant protein-1 (MCP-1) in HIV associated normotensive and pre-eclamptic 
pregnancies. 
Methods: Following ethical approval and written consent, urine samples were collected from 
HIV negative (HIV –ve) normotensive pregnant (n=19), HIV positive (HIV +ve) 
normotensive pregnant (n=19), HIV –ve pre-eclamptic (n=19) and HIV +ve pre-eclamptic 
(n=19) women. The concentrations of KIM-1, calbindin, IL-18 and MCP-1 were assessed 
using the Bioplex technology. 
Results: In contrast to IL-18 (p >0.05) and MCP-1 (p >0.05), the concentrations of KIM-1 (p 
= 0.02) and calbindin (p = 0.02) were significantly higher in PE compared to normotensive 
pregnancies, irrespective of HIV status. Based on HIV status, all 4 analytes were similar 
between HIV +ve and HIV -ve groups. Urinary KIM-1 levels in the HIV –ve pre-eclamptics 
were significantly higher than those in the HIV –ve normal pregnancies (p = 0.007). 
Conclusion: Our results demonstrate an increase in the urinary level of kidney injury molecule-1 
and calbindin in PE, implicating their possible value as biomarkers of kidney injury. We 
observed no differences in the levels of KIM-1, IL-18, MCP-1 and calbindin based on HIV 
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status. We suggest that studies with larger sample sizes using these markers be conducted to 
establish their use as markers of diagnosing kidney injury in PE. 
 





























































Pre-eclampsia (PE) is a hypertensive disorder of pregnancy characterized by an elevation in 
blood pressure and proteinuria after the 20th week of gestation (1). Pre-eclampsia (PE) is a 
major public health problem and is a leading cause of maternal and foetal morbidity and 
mortality globally (1). The exact cause of PE remains unknown despite extensive research to 
understanding its pathophysiology and mechanism of development (2). 
Pre-eclampsia is associated with inadequate trophoblast invasion and with spiral artery 
remodelling limited to the decidua (3, 4). The subsequent decreased blood flow results in the 
placental hypoxia and oxidative stress with consequential elevated apoptosis and necrosis (5). 
This leads to release of placental-derived debris into the circulation, which stimulate an 
exaggerated maternal systemic inflammatory response and results in injury to maternal 
endothelial tissue (6). Endothelial damage is widespread and affects different organ systems 
in the body such as the kidney, liver, brain, heart and lungs (7). 
In normal pregnancy, there is a change in renal and systemic hemodynamic, the mechanisms 
responsible for this physiologic change plays important roles in the response of the renal 
system to the new changes in fluids and electrolytes (7). Glomerular filtration rate (GFR) 
increases post conception, reaching around 50% above the baseline value, this results in 
significant hyperfiltration during the second trimester; after which GFR then falls by 
approximately 20%, returning to the levels at which it was during the antepartum period 3 
months post-delivery (7, 8). Pregnancies complicated with PE are associated with renal 
hyperfiltration, elevated urinary protein and a hypercoagulable state that influence kidney 






excretion is associated with pathologic alteration in renal glomerular endotheliosis, a 
hallmark of PE, although the underlying mechanism for this lesion is elusive (10-12) 
The kidney injury molecule –1 (KIM-1) is produced by cells of the renal tubular epithelium 
and interstitial macrophages (19, 20). The level of KIM-1 is low in concentration during 
normal physiological state but its expression is significantly elevated in kidney diseases (21, 
22). An increase in the level of urinary KIM-1 concentrations is indicative of ischemic injury 
of the kidney (12). 
IL-18 is a biomarker specific for kidney injury depicting ischemic injury of the proximal 
tubules. In the absence of kidney injury, only traces of urinary IL-18 is seen, yet its 
concentration is raised by several folds during injury (19). 
Calbindin also known as calbindin-D28K, is an intracellular calcium binding protein, 
localised in the distal tubular cells and also in the proximal part of the collecting duct (23, 
24). Injury to the distal segment of the nephron affects the expression of calbindin thus 
altering the concentration of urinary calbindin (23). 
The molecule monocyte chemoattractant protein-1 (MCP-1) correlates with renal function 
outcome and albuminuria (25). This molecule is expressed in the tubular epithelial cells and 
in white cells which infiltrate the interstitium of the tubules, hence they are the source of 
MCP-1 in the urine (26). 
Since the kidney is a target organ in PE, it is important to study the urinary biomarkers of 
kidney injury (KIM-1, IL-18, calbindin, and MCP-1). This study aims to evaluate the level of 
these markers of kidney injury in the urine of HIV positive and negative women with 








Post ethical approval (BREC- No.BE302/16) and informed consent was obtained. Urine 
samples were obtained from normotensive (N) and pre-eclamptic (PE) women in the 
antenatal ward of a large regional hospital in Durban, South Africa. These 2 study groups 
were further stratified by HIV status (HIV +ve and HIV -ve). Demographic and clinical 
characteristics were collated onto a structured datasheet. 
Women who had no history of pregnancy complications were used as controls. Pre-eclampsia 
was defined by a blood pressure ≥ 140/90 mm Hg and proteinuria ≥ 300 mg in a 24-hour 
urine sample. Women with a history of chronic hypertension, cardiovascular or renal disease, 
diabetic mellitus, bleeding disorders, and previous history of any medical conditions were 
excluded. 
Spot urine samples was obtained from patients. Importantly, less than 20 minutes after 
collection, the urine samples were centrifuged at 1500 rpm for 10 min to remove residual 
cells and then stored at -80°C until Bioplex assay. 
Urinary KIM-1, calbindin, IL-18 and MCP-1 were quantified using a BIO-RAD Human 
Kidney Toxicity Assay Panel 2 (BIO-RAD Laboratories). The assays are built on magnetic 
beads to enable robust quantification of multiple proteins in human urine samples. Samples 
were analysed based on the manufacturer’s instructions and guidelines. 
 
Data obtained in this study was analysed using a BioPlex 200 instrument equipped with Bio-Plex 
Manager™ analysis software version 4.1. A standard curve was produced using the known 
concentration (ng/ml) of each analytes by plotting the median fluorescent intensity (MFI) signal 
against concentration. These standards were used to interpolate the concentration of the unknown 
samples. 
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Intra plate variability was determined using determined with CV ˂20% and ( ) 




GraphPad Prism, V 5.03 was used for data analysis (Graph-Pad Software Inc., California). One-way 
analysis of variance and t-test were used to compare the experimental results between the different study 
groups. A p-value less than 0.05 was considered significant. 
 
Demographic and clinical data: 
 
The patient demographic and clinical data is presented in Table 1. There was a significant difference in 
maternal age (p = 0.003) across the study groups. Gestational age, parity and maternal weight were non-
significant amongst the study groups. A significant difference was observed in both systolic (p = 





Pregnancy type: Data obtained from the analysis of the urinary levels of KIM-1, IL-18, calbindin, and 
MCP-1 are presented in Tables 2a, 2b, and 2c and the specificity of each of the markers are illustrated in 
figures 1A, 2A, 3A and 4A respectively. Urinary IL-18 and MCP-1 levels were not statistically 
significant according to pregnancy type (pre-eclamptic vs normotensive) respectively (p = 0.90, p = 
0.50). There was a significant difference in the concentration of KIM-1 and calbindin between PE and N 
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HIV status; There was no significant difference in the urinary levels of KIM-1, IL-18, 
calbindin, and MCP-1 concentration in the HIV-ve compared to the HIV +ve women (p = 
0.47, p = 0.28, p = 0.99, p = 0.78). 
Comparison across the study groups; Urinary KIM-1 levels was significantly different across 
the study groups (p = 0.0001) whilst IL-18, calbindin, and MCP-1 were not significant 
respectively (p = 0.99, p = 0.28, p= 0.73). These observations are pictorially illustrated in 





This study demonstrates that there was a significant difference in the concentrations of KIM-
1 and calbindin between PE and N pregnancies. However, based on pregnancy type, IL-18 
and MCP-1 were not statistically significant. 
We report a twofold higher level of KIM-1 in PE compared to that in N pregnancy irrespective of 
the HIV status. This increase in urinary KIM-1 concentration is in accordant with findings from 
similar studies that have demonstrated an increase in urinary KIM-1 concentrations in PE 
 
(7). Wang et al., (2015) (12) have shown that the urinary concentration of KIM-1 was affected by 
the severity of PE, as the level was significantly higher in severe PE compared to the urinary 
KIM-1 concentration in patients with mild form of the disorder. It is well known that PE is 
associated with the characteristic glomerular endotheliosis, widespread ischemic injury as well as 
altered functional integrity of the glomerular and proximal tubular cells (7, 22). 
 
In this study, irrespective of HIV status, urinary calbindin level was significantly higher in PE 
compared to N pregnancies. This increase is corroborated in a previous study (23). Notably, 
urinary calbindin meets the criteria for use as an ideal biomarker for the prediction of kidney 
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injury because it is released by the distal tubular cells of injured kidney, where it is involved 
in Ca2+ reabsorption (23). Moreover, calbindin can be used to monitor the development and 
progression of injury to the distal convoluted tubule of the nephron (31). 
Based on pregnancy type, the results of this study demonstrate similar urinary IL-18 levels 
between the PE and N groups. These results are in keeping with the findings of Lopez-Hernandez 
et al., (2016) (27). Also, another study has highlighted that urinary IL-18 is not beneficial as a 
urinary biomarker for the detection of acute kidney injury (28). IL-18 is a mediator of renal 
ischemic reperfusion injury that induces monocyte and neutrophil infiltration of the renal 
parenchyma, it is well know that PE is associated with ischaemia. Also, IL-18 increases in the 
urine during apoptosis (29), PE is considered to be associated with increased apoptosis (5). 
Furthermore, IL-18 activity is enhanced in a number of inflammatory diseases (Gracie et al., 
2003) (37) and PE represents an exaggerated inflammatory response. 
 
The role for IL-18 in various pathological conditions are currently of great interest and its role in 
acute or chronic inflammatory conditions such as PE remains ambiguous. IL-18 is a pro-
inflammatory cytokine and IL-18 is widely considered as a biomarker of tubular cell 
injury/necrosis in a kidney exposed to ischemic injury (29, 30). In this study, urinary IL-18 levels 
in the PE group were similar to the N group. These results are in keeping with the findings of 
Waanders et al (2009) (21). However, the circulating levels of cytokines particularly IL-18 in 
pre-eclampsia are however, conflicting. In contrast to PE, the shift to a Th2 immune response 
does not occur resulting in an increase in Th1 cytokines. The elevation of a pro-inflammatory 
cytokine (IL-18) may trigger the exaggerated inflammatory process in PE, however, we were 
unable to show this effect. Importantly, in HIV +ve patients there is a decrease in the Th1 and an 




that the HIV infection may explain the similarity in the IL-18 levels observed between our 
study groups. In our study, urinary IL-18 level in the HIV negative and positive women with 
PE did not statistically vary from that in the HIV-ve and HIV +ve women with normal 
pregnancy. The unexpected similarity of IL-18 levels between PE and N pregnancies may be 
attributed to the fact that all HIV +ve women in this study received anti-retroviral drug 
(ARV) therapy, a side effect of which is nephrotoxicity (12). 
This study does not report a significant difference in the urinary MCP-1 level in PE compared 
normotensive pregnancy. These findings are similar to that of Lopez-Hernandez (2016) (27). 
Although MCP-1 is known to mediate acute ischemic kidney injury (32), it is confirmed by an 
in-vitro study that MCP-1 specifically activates cells of the tubular epithelium (26). 
 
Based on HIV status, we report no significant difference in urinary KIM-1, calbindin, IL-18 and 
MCP-1 concentration in the study population. This lack of significance may be attributed to the 
fact that it is a national standard of care within antenatal facilities in South Africa for HIV +ve 
women to receive antiretroviral therapy and prevention of mother-to-child transmission of HIV 
(PMTCT). The use of highly active antiretroviral therapy (HAART) has helped reduce mortality 
and morbidity (13). However, individuals with HIV +ve may develop chronic metabolic 
conditions associated with the use of HAART like diabetes and dyslipidaemia. These metabolic 
disorders may lend support to vascular and renal dysfunction (13). Acute kidney injury seen in 
HIV infection mostly are a product of opportunistic infections than the toxic effect of ART drugs. 
Studies have demonstrated that nephrotoxicity from antiretroviral therapy accounts for 
approximately 14% of late-onset cases of acute kidney injury (14). A major cause of kidney 






may occur as a result of HIV infection itself, or the presence of an opportunistic infection or 
direct drug cytotoxicity (13, 15). 
Normal kidney function is crucial to the metabolism and excretion of antiretroviral drugs, this 
exposes the kidney to insult from some of these therapeutic agents (16). Asides nephrotoxicity 
associated with the use of ART drugs, the HIV can directly cause injury to the renal cells, this 
can be seen in cases of HIV-associated nephropathy (17, 18). Other conditions which result from 
HIV infection that affects kidney function include HIV immune-complex kidney disease and 
thrombotic microangiopathy resulting from infection with the virus (16). 
 
Though studies have shown that HIV +ve patients have an increased chance developing acute 
kidney injury and also chronic disorder of the kidney (33). The chance of HIV +ve 
individuals suffering nephrotoxicity and nephron angiosclerosis is also increased compared 
to that in HIV –ve persons (34, 35). It is estimated that approximately 30% of acute kidney 
injury episodes in HIV +ve people is due to nephrotoxicity which may be due to treatment 
with anti-retroviral therapy (36). Drugs used in the treatment of HIV associated infections 
have been linked to the development of kidney conditions. Though the chance of a single or 
particular antiretroviral drug causing renal toxicity is low, so many factors are implicated in 
making HIV +ve individuals susceptible in developing kidney injury (33). The plasma levels 
of MCP-1 correlates with virus load in HIV infection (39, 40). Moreover, MCP-1 levels are 
diminished in HIV-ve patients after Indinavir (a viral protease inhibitor) treatment (41) and 
all HIV+ve women in this study were on ARV therapy. 
 
In conclusion, our results demonstrate an increase in the urinary concentration of KIM-1 and 
calbindin, whilst the urinary IL-18 and MCP-1 in PE did not show any significant difference 
when compared to normotensive pregnancies. 
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We proposed that the biomarkers could be established as an indicator of renal injury and 
should be used on a more larger sample size of normotensive and pre-eclamptic patients in 
diagnosing kidney damage. 
 
 
Conflict of interest 
 







The authors wish to thank the institutional biostatistician, Dr. C Connolly. Financial support 










































1. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. The hypertensive disorders of pregnancy. 
Best 
 
Pract & Res Clin Obst & Gynaecol 2015; 29(5):643-57. 
 
 
2. Hutcheon JA, Lisonkova S, Joseph K. Epidemiology of pre-eclampsia and the other hypertensive 
disorders of pregnancy. Best Pract & Res Clin Obst & Gynaecol 2011; 25(4):391-403. 
 
3. Granger JP, Alexander BT, Bennett WA, Khalil RA. Pathophysiology of pregnancy-induced 
hypertension. Am J Hyper 2001; 14(S3):178S-85S. 
 
4. Staff AC, Benton SJ, von Dadelszen P, Roberts JM, Taylor RN, Powers RW, et al. Redefining 
preeclampsia using placenta-derived biomarkers. Hyper 2013; 61(5):932-42. 
 
5. Tannetta D and Sargent I. Placental disease and the maternal syndrome of preeclampsia: missing 
links? Curr Hypert Rep 2013; 15(6):590-9. 
 
6. Redman CW and Sargent IL. Latest advances in understanding preeclampsia. Sci 2005; 
308(5728):1592-4. 
 
7. Xiao J, Niu J, Ye X, Yu Q and Gu Y. Combined biomarkers evaluation for diagnosing kidney 
injury in preeclampsia. Hyper in Preg 2013; 32(4):439-49. 
 
8. Krane NK and Hamrahian M. Pregnancy: kidney diseases and hypertension. Am J Kid Dis. 
2007;49(2):336-45. 
 
9. Machado S, Figueiredo N, Borges A, Pais M, Freitas L, Moura P, et al. Acute kidney injury in 
pregnancy: a clinical challenge. J Nephrol 2012; 25(1):19-30 
 
10. Garovic VD, Wagner SJ, Turner ST, Rosenthal DW, Watson WJ, Brost BC, et al. Urinary 
podocyte excretion as a marker for preeclampsia. Am J Obstet Gynecol 2007; 196(4):320. e1-e7. 
 
35 
11. Tesch GH. Review: Serum and urine biomarkers of kidney disease: A pathophysiological 
perspective. Nephrol 2010; 15(6):609-16. 
 
12. Wang Y, Gu Y, Loyd S, Jia X, Groome LJ . Increased urinary levels of podocyte glycoproteins, 
matrix metallopeptidases, inflammatory cytokines, and kidney injury biomarkers in women with 
preeclampsia. Am J Physiol-Renal Physiol 2015; 309(12):F1009-F17. 
 
13. Izzedine H, Harris M, Perazella MA. The nephrotoxic effects of HAART. Nat Rev Nephrol 
2009; 5(10):563-73. 
 
14. Roe J, Campbell LJ, Ibrahim F, Hendry BM, Post FA. HIV care and the incidence of acute renal 
failure. Clin Infect Dis 2008; 47(2):242-9. 
 
15. Rho M and Perazella MA. Nephrotoxicity associated with antiretroviral therapy in HIV-infected 
patients. Curr Drug Safety 2007; 2(2):147-54. 
 
16. Kalyesubula R and Perazella MA. Nephrotoxicity of HAART. AIDS Res and Treat 2011; 2011: 
562790. 
 
17. Campbell L, Ibrahim F, Fisher M, Holt S, Hendry B, Post F. Spectrum of chronic kidney disease 
in HIV‐infected patients. HIV Med 2009; 10(6):329-36. 
 
18. Choi AI, Shlipak MG, Hunt PW, Martin JN, Deeks SG. HIV-infected persons continue to lose 
kidney function despite successful antiretroviral therapy. AIDS (London, England) 2009; 
23(16):2143. 
 
19. Liu Y, Guo W, Zhang J, Xu C, Yu S, Mao Z, et al. Urinary interleukin 18 for detection of acute 







20. Parikh CR, Jani A, Melnikov VY, Faubel S, Edelstein CL. Urinary interleukin-18 is a marker of 
human acute tubular necrosis. Am J Kid Dis 2004; 43(3):405-14. 
 
21. Waanders F, Vaidya VS, van Goor H, Leuvenink H, Damman K, Hamming I, et al. Effect of 
renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on 
urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc 
analysis of a randomized controlled trial. Am J of Kid Dis 2009; 53(1):16-25. 
 
22. Zhang Z, Humphreys BD, Bonventre JV. Shedding of the urinary biomarker kidney injury 
molecule-1 (KIM-1) is regulated by MAP kinases and juxtamembrane region. J Am Soc Nephrol 
2007; 18(10):2704-14. 
 
23. Iida T, Fujinaka H, Xu B, Zhang Y, Magdeldin S, Nameta M, et al. Decreased urinary calbindin 
1 levels in proteinuric rats and humans with distal nephron segment injuries. Clin Exp Nephrol 
2014;18(3):432-43. 
 
24. Hemmingsen C. Regulation of renal calbindin-D28K. Pharmacol & Toxicol 1999; 87:5-30. 
 
 
25. Murea M, Register TC, Divers J, Bowden DW, Carr JJ, Hightower CR, et al. Relationships 
between serum MCP-1 and subclinical kidney disease: African American-Diabetes Heart Study. 
BMC Nephrol 2012; 13(1):1. 
 
26. Viedt C and Orth SR. Monocyte chemoattractant protein‐1 (MCP‐1) in the kidney: does it 
more than simply attract monocytes? Nephrol Dial Trans 2002; 17(12):2043-7. 
 
27. Lopez-Hernandez Y, Saldivar-Nava JA, Garza-Veloz I, Delgado-Enciso I, Martinez-de-
Villarreal LE, Yahuaca-Mendoza P, et al. Nested case–control study reveals increased levels of 
urinary proteins from human kidney toxicity panels in women predicted to develop 
preeclampsia. Int Urol Nephrol 2016; 48(12):2051-9. 
 
37 
28. Hristova J and Dimitrova A. NGAL, IL-18, and KIM the risk of developing acute k undergoing 
cardiopulmonary bypass. Res J Med & Med Sci 2015; 3(6): 228-283 
 
29. Adiyanti SS and Loho T. Acute kidney injury (AKI) biomarker. Acta Med Indones 2012; 
44(3):246-55. 
 
30. Parikh C, Jani A, Mishra J, Ma Q, Kelly C, Barasch J, et al. Urine NGAL and IL‐18 are 
predictive biomarkers for delayed graft function following kidney transplantation. Am J Transp 
2006; 6(7):1639-45. 
 
31. Guha M, Heier A, Price S, Bielenstein M, Caccese RG, Heathcote DI, et al. Assessment of 
Biomarkers of Drug-induced Kidney Injury in Cynomolgus Monkeys Treated with a Triple Re-
uptake Inhibitor. Toxicological Sciences 2011; 120(2): 269-283. 
 
32. Munshi R, Johnson A, Siew ED, Ikizler TA, Ware LB, Wurfel MM, et al. MCP-1 gene 
activation marks acute kidney injury. J Am Soc Nephrol 2011; 22(1):165-75. 
 
33. Campos P, Ortiz A, Soto K. HIV and kidney diseases: 35 years of history and consequences. 
Clin Kid J 2016; 1-10. 
 
34. Rosenberg AZ, Naicker S, Winkler CA, Kopp JB. HIV-associated nephropathies: epidemiology, 
pathology, mechanisms and treatment. Nat Rev Nephrol 2015; 11(3):150-60. 
 
35. Saracho R, Escobar EM, Farnés JC, Arcos E, Blanca AM, Govantes MÁG, et al. Clinical 
evolution of chronic renal patients with HIV infection in replacement therapy. Nefrología 
(English Edition) 2015; 35(5):457-64. 
 
36. Randall D, Brima N, Walker D, Connolly J, Laing C, Copas A, et al. Acute kidney injury among 




37. Gracie JA, Robertson SE, and McInnes IB. Interleukin-18. J Leukoc Biol 2003; 73(2): 213-224 
 
 
38. Clerici M and Shearer GM. A TH1→TH2 switch is a critical step in the etiology of HIV 
infection. Immunol Today 1993; 14(3): 107-111. 
 
39. Weiss L, Si-Mohamed A, Giral P, Castiel P, Ledur A, Blondin C et al. Plasma levels of 
monocyte chemoattractant protein-1 but not those of macrophage inhibitory protein-1alpha and 
RANTES correlate with virus load in human immunodeficiency virus infection. J Infect Dis 
1997; 176(6): 1621-1624 
 
40. Chang L, Ernst T, St Hillaire C and Conant K. Antiretroviral treatment alters relationship 
between MCP-1 and neurometabolites in HIV patients. Antiviral Therap 2004; 9:431-440. 
 
41. Bisset LR, Rothen M, Joller-Jemelka HI, Dubs RW, Grob PJ, et al., Change in circulating levels 
of the chemokines macrophage inflammatory proteins 1 alpha and 11 beta, RANTES, monocyte 
chemotactic protein-1 and interleukin-16 following treatment of severely immunodeficient HIV-





























Tables and Figures 
 
Table 1. Demographic and clinical data for the different study groups. 
 
 Normotensive Normotensive Pre-eclamptic Pre-eclamptic p-value 
 pregnant women pregnant pregnant women pregnant women  
 (HIV-ve) women (HIV-ve) (HIV +ve)  
  (HIV +ve)    
      
Sample size n=19 n=19 n=19 n=19  
      
Age (years) 28 (23 – 32) 30 (23 – 36) 23 (19 – 32) 33 (30 – 34)* p = 0.03 
      
Gestational age 36 (34 – 37) 36 (30 – 39) 38 (36 – 39) 37 (36 – 38) ns 
(weeks)      
      
Parity 1 (1 – 2) 2 (1 – 2) 1 (1 – 3) 2 (1-3) ns 
      
Maternal 0.15 (0.02 – 0.99) 0.14 0.01 – 1.6 0.22 (0.0 – 4.5) 0.11 (0.01 – 2.7) ns 
weight      
(kg)      
      
Systolic BP 109 (106 – 117) 104 (98 – 120) 162 (152 – 154 (145 – 159) p < 0.001 
(mmHg)   173)*   
      
Diastolic BP 69 (63 – 72) 65 (60 – 74) 97 (92 – 108) 96 (90 – 100) p < 0.001 
(mmHg)      
      
 




























Table 2a. Urinary level of kidney toxicity biomarkers normal pregnancy and in pre-eclampsia 
 
 Normotensive Pre-eclamptic pregnant p-value 
 pregnant women women  
     
Sample size n=38  n=38  
       
KIM-1(ng/ml) 0.04 (0.01 – 0.2) 0.06 (0.01 – 1.1)* p < 0.05 
       
IL-18 (ng/ml) 0.02 (0.01 – 0.14) 0.01 (0.01 – 0.25) ns 
     
Calbindin 44.1 (4.0 – 556.1) 68.5(7.5 – 3022)* p < 0.05 
(ng/ml)       
     
MCP-1(ng/ml) 0.13(0.01 – 2.7) 0.17 (0.0 – 4.4) ns 
       
 














































Table 2b. Urinary level of kidney toxicity biomarkers in HIV –ve and HIV +ve groups 
 
 HIV –ve HIV+ve  p-value 
     
Sample size n=38 n=38   
    
KIM-1(ng/ml) 0.07, (0.01 – 0.41) 0.03, (0.01 – 1.1) ns 
     
IL-18 (ng/ml) 0.02 (0.01 – 0.14) 0.01 (0.01 – 0.25) ns 
    
Calbindin 44.8(4.0 – 609.1) 61.0(7.5 – 3022) ns 
(ng/ml)     
     
MCP-1(ng/ml) 0.18(0.0 – 4.5) 0.13( 0.01 – 2.7) ns 
     
 
















































Table 2c. Urinary level of kidney toxicity biomarkers across 
study groups. 
 
 Normotensive Normotensive Pre-eclamptic Pre-eclamptic p-value 
 pregnant women pregnant pregnant women pregnant women  
 (HIV-ve) women (HIV-ve) (HIV+ve)  
  (HIV+ve)    
      
Sample size n=19 n=19 n=19 n=19  
       
KIM-1(ng/ml) 0.03 (0.01 – 0.16) 0.05 (0.01 – 0.09 (0.01 – 0.04(0.01 – 1.1) p < 0.05 
  0.2)  0.41)*   
       
IL-18 (ng/ml) 0.02 (0.01 – 0.14) 0.01 (0.01 – 0.01(0.01 – 0.02 (0.01 – ns 
  0.09) 0.06) 0.25)  
       
Calbindin (ng/ml) 46.0 (4.0 – 556.1) 42.5 (7.5 – 36.7 (7.5 – 36.7(7.5 – ns 
  246.9) 609.1) 609.1)  
      
MCP-1(ng/ml) 0.15 (0.02 – 0.99) 0.14, 0.01 – 1.6 0.22 (0.0 – 4.5) 0.11 (0.01 – 2.7) ns 
       
 
















































































































































































































































































Figure 2B.  Urinary IL-18 level in HIV infected and uninfected women with normal pregnancy 





















































































































































































































































































Figure 4B. Urinary MCP-1 level in HIV infected and uninfected women with normal pregnancy 


















































































































Extensive research has led to a sound understanding of the kidney’s response in physiologic 
and pathologic conditions. This has led to the detection of certain genes and molecules that 
play a critical role in kidney function. Of note, is the fact that several of these proteins are 
present hence measurable in the urine, thereby serving as non-invasive biomarkers for the 
study of the kidney disorders (Hristova and Dimitrova, 2015). Studies have implicated the 
urinary concentration of these markers to the state of the kidney (Xiao et al., 2013; Wang et 
al., 2012). However, further research is warranted to establish the different tissues where 
these proteins are located in the kidney so that the urinary concentration can serve as a mirror 
image of the kidney function. 
 
 
Kidney tubular function is altered in PE (Machado et al., 2012). Associated with PE is renal 
hyper filtration, elevated urinary protein and a hypercoagulable state which all contribute to 
influencing kidney function in PE (Xiao et al., 2013). The knowledge of the kidney being a 
target organ in hypertensive complications of pregnancy has progressed. Kidney injury in PE 
is characterised by lesions of the glomerulus, endotheliosis and loss of glomerular function. 
This has led to PE being considered a common glomerular disease (Reckelhoff, 2012; 
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A study by Wang et al., has shown that the urinary protein concentration of specific proteins 
of glomerular origin are elevated in the urine of women with PE compared to their level in 
normotensive pregnant women (Wang et al., 2012), and are also lower compared to women who 
were hypertensive prior to getting pregnant. The same study report that these proteins are 
significantly higher in PE irrespective of the measurement, if it was absolute value measured or if 
they were factored for urinary creatinine (Wang et al., 2012). The current study attempts to 
quantify the urinary level of KIM-1, IL-18, calbindin and MCP-1 as biomarkers for the detection 
of kidney injury in HIV associated normotensive and pre-eclamptic pregnant women.  
 
 
In this present study, we observed the urinary KIM-1 concentration in PE was significantly 
higher than normotensive pregnancies. This increase in urinary KIM-1 concentration is in 
keeping with findings from similar studies that have also shown an increase in urinary KIM-1 
concentration in PE (Xiao et al., 2013). Wang et al., (2015) suggests that the urinary 
concentration of KIM-1 is affected by the severity of PE, as the level was significantly higher 
in severe PE compared to the mild form of the disorder. This increase in urinary KIM-1in PE 
is associated with the increased incidence of endotheliosis, ischemia reperfusion injury of the 
kidney, and damage to cells of the kidney proximal tubules (Xiao et al., 2013, Zhang et al., 
2007). In a normal kidney, the expression of KIM-1 is low, but it is intensely up- regulated 
after injury to the kidney. 
 
This molecule is a phosphatidylserine receptor which converts epithelial cells into phagocytic 
cells via the recognition of cell surface-specific epitopes which present on apoptotic tubular 
epithelial cells (Ichimura et al., 2008).  
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It also known that an extracellular domain of the molecule KIM-1 is proteolytically processed 
and appears in the urine immediately after injury to the kidney especially in acute kidney injury 
(Hristova and Dimitrova, 2015). Studies have shown that western and northern blot analysis of 
KIM-1 mRNA transcripts and its protein are up regulated in in vivo post ischemic kidney injury 
(Ichimura et al., 1998). In situ hybridization and immunohistochemistry studies have also shown 
KIM-1 expression on injured cells of the proximal tubule, this is commonly seen in the medulla 
(Ichimura et al., 1998). 
 
 
We report that the urinary IL-18 level in the PE group was not significantly different to the 
normotensive pregnant group. This result is in keeping with the findings of a similar studies 
(Lopez-Hernandez et al., 2016; Wang et al., 2015). The cytokine IL-18 is pro-inflammatory and 
the level of this molecule in the urine is considered as a marker of tubular cell injury/necrosis in a 
kidney exposed to ischemic injury (Adiyanti and Loho, 2012, Parikh et al., 2006). A study has 
also shown that urinary IL-18 concentration was not beneficial as a urinary biomarker in the 
detection of acute kidney injury (Hristova and Dimitrova, 2015). Moreover, IL-18 is known to 
promote or drive cellular apoptosis and has the potential of complicating kidney injury. Small 
amounts of IL-18 are found in the urine in physiological conditions but its level is greatly 
increased in cases of kidney injury (Hristova and Dimitrova, 2015). 
 
 
In this study, irrespective of HIV status urinary calbindin level was significantly higher in PE 
compared to normotensive pregnancies. This increase  corroborates a previous study by (Iida et 
al., 2014).  
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Studies have shown that a significant concentration of calbindin is expelled into human urine in 
cases of kidney injury. The urinary concentration is tied to onset of disease and the time of 
diagnosis (Iida et al., 2014), as alteration in the calbindin expression in renal cells impact the 
urinary calbindin levels in kidney toxicity (Iida et al., 2014).  
Notably, urinary calbindin meets the criteria for use as an ideal biomarker for the prediction of 
kidney injury because it is derived from release by injured kidney distal tubular cells, where it 
is involved in Ca2+ reabsorption (Iida et al., 2014). Moreover, calbindin can be used to 
monitor the development and progression of injury to the distal convoluted tubule of the 
nephron (Guha et al., 2011). 
 This study does not report a significant difference in the urinary MCP-1 level in PE 
compared to normotensive pregnancy. These findings are similar to that of (Lopez-
Hernandez et al., 2016). Although MCP-1 is known to mediate acute ischemic kidney injury 
(Munshi et al., 2011), it is confirmed by an in-vitro study that MCP-1 specifically activates 
cells of the tubular epithelium (Viedt and Orth, 2002). An increase in the urinary MCP-1 
level correlates with the concentration of albumin and protein excretion into the urine in 
cases of kidney injury (Stephan et al., 2002). The exact cellular source for the release of 
MCP-1 still remains a debate as it is not clearly defined (Munshi et al., 2011). Studies have 
shown it could be released in cases of injured glomeruli, from the proximal tubules, distal 
segment of the kidney nephron, and  from inflammatory cells, hence MCP-1 in the urine may 
not reflect a specific area of injury to the kidney (Zager et al., 2008). 
 
Based on HIV status, we report no significant difference in urinary KIM-1, calbindin, IL-18 
and MCP-1 concentration in our study population.  
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This lack of significant differencee may be attributed to the fact that it is a national standard 
of care within antenatal facilities in South Africa for HIV infected women to receive 
antiretroviral therapy and prevention of mother-to-child transmission of HIV (PMTCT). The 
use of highly active antiretroviral therapy (HAART) has helped reduce mortality and 
morbidity (Izzedine et al., 2009). However, individuals infected with HIV may develop 
chronic metabolic conditions associated with the use of HAART like diabetes and 
dyslipidaemia. These metabolic disorders may lend support to vascular and renal dysfunction 
(Izzedine et al., 2009). Acute kidney injury seen in HIV infection are  mostly a product of the 
opportunistic infections than the toxic effect antiretroviral drugs. Studies have demonstrated 
that nephrotoxicity from antiretroviral therapy accounts for approximately 14% of late-onset 
cases of acute kidney injury (Roe et al., 2008). A major cause of kidney injury in HIV 
infection is acute interstitial nephritis which be due to HIV infection itself, or the presence of 




Normal kidney function is crucial to metabolism and excretion of antiretroviral drugs, this 
exposes the kidney to insult from  some of these therapeutic agents (Kalyesubula and 
Perazella, 2011). Asides nephrotoxicity associated with the use of antiretroviral drugs, the 
HIV can directly cause injury to the renal cells, this can be seen in cases of HIV-associated 
nephropathy (Campbell et al., 2009; Choi et al., 2009). Other conditions which results from 
HIV infection that affects kidney function include HIV immune-complex kidney disease and 
thrombotic microangiopathy resulting from infection with the virus (Kalyesubula and 
Perazella, 2011). 
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Though studies have shown that HIV infected patients have an increased chance developing 
acute kidney injury and also chronic disorder of the kidney (Campos et al., 2016).  
The chance of HIV infected individuals suffering nephrotoxicity and nephron angiosclerosis is 
also increased compared to that in uninfected persons (Rosenberg et al., 2015; Saracho et al., 
2015). It is estimated that approximately 30% of acute kidney injury episodes in HIV infected 
people is due to nephrotoxicity which may be due to treatment with anti-retroviral therapy 
(Randall et al., 2015). Drugs used in the treatment of HIV associated infections have been 
linked to the development of kidney conditions. Though the chance of a single or particular 
antiretroviral drug causing renal toxicity is low, so many factors are implicated in making 
HIV infected individuals susceptible in developing kidney injury (Campos et al., 2016). The 
plasma levels of MCP-1 correlates with virus load in HIV-1 infection (Weiss and others 
1997; Chang and others 2004). Moreover, MCP-1 levels are diminished in HIV-1 patients 
after indinavir (a viral protease inhibitor) treatment (Bisset et al., 1997) and all infected 







Our results demonstrate an increase in the urinary level of kidney injury molecule-1 and 
calbindin in PE, implicating their value as biomarkers of kidney injury. To our knowledge 
this is also the first study reporting no significant difference in the levels of KIM-1, IL-18, 
MCP-1 and calbindin based on HIV status.  
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The molecules studied in this research viz.,  KIM-1 and calbindin.IL-18, and MCP-1 provide 
the source of biomarkers for non-invasive diagnosis of pre-eclampsia using urine samples. 
3.3 Recommendation 
 
We propose that since these markers are promising, studies with larger sample sizes and case 
control studies are required. Also, the severity of pre-eclampsia may affect the concentration 
of this markers in the urine, we propose that the level of these markers be investigated in the 
different forms of pre-eclampsia like mild to moderate pre-eclampsia and in severe pre-
eclampsia or in early onset or late-onset pre-eclampsia since studies have shown these two 
conditions are different entities and should be treated as such. 
Research in this field has demonstrated that hypertensive disorders of pregnancy may 
predispose the woman to developing cardiovascular complications later in life and also 
exposing the foetus to adverse conditions that may hinder fetal development or impair other 
life processes after birth. Therefore, it is appropriate and necessary to develop diagnostic 
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